Dr. Ian Flinn, MD
Claim this profileSarah Cannon Research Institute
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
17 reported clinical trials
23 drugs studied
About Ian Flinn, MD
Education:
- Earned an MD (Doctor of Medicine).
- Completed a PhD in Clinical Investigations.
Experience:
- Served as the Director of Blood Cancer Research at Sarah Cannon Research Institute.
- Authored over 240 scientific manuscripts.
- Held a leadership role in clinical research at the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Appointed as Associate Professor of Oncology at Johns Hopkins.
- Recently became the Chief Scientific Officer at OneOncology and Tennessee Oncology.
Area of expertise
1Lymphoma
CD19 positive
MYC positive
BCL2 positive
2Non-Hodgkin's Lymphoma
CD19 positive
MYC positive
BCL2 positive
Affiliated Hospitals
Clinical Trials Ian Flinn, MD is currently running
Brentuximab Vedotin + Nivolumab
for Hodgkin's Lymphoma
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune system to better fight Hodgkin lymphoma cells. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant treatment and spare the considerable cost and toxicity on transplantation.
Recruiting1 award Phase 224 criteria
Tazemetostat + Lenalidomide + Rituximab
for Follicular Lymphoma
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.
Recruiting1 award Phase 34 criteria
More about Ian Flinn, MD
Clinical Trial Related6 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Ian Flinn, MD has experience with
- Nivolumab
- Brentuximab Vedotin
- CD30.CAR-T
- CLBR001
- Rituximab
- Doxorubicin
Breakdown of trials Ian Flinn, MD has run
Lymphoma
Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ian Flinn, MD specialize in?
Ian Flinn, MD focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved CD19 positive patients, or patients who are MYC positive.
Is Ian Flinn, MD currently recruiting for clinical trials?
Yes, Ian Flinn, MD is currently recruiting for 3 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Ian Flinn, MD has studied deeply?
Yes, Ian Flinn, MD has studied treatments such as Nivolumab, Brentuximab Vedotin, CD30.CAR-T.
What is the best way to schedule an appointment with Ian Flinn, MD?
Apply for one of the trials that Ian Flinn, MD is conducting.
What is the office address of Ian Flinn, MD?
The office of Ian Flinn, MD is located at: Sarah Cannon Research Institute, Nashville, Tennessee 37203 United States. This is the address for their practice at the Sarah Cannon Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.